Michaela T. Hall

TL;DR: In this paper, the authors used Policy1-Cervix, an extensively validated dynamic model of HPV vaccination, natural history, and cervical screening, to estimate the age-standardised incidence of cervical cancer in Australia from 2015 to 2100.

TL;DR: Primary HPV screening every 5 years with partial genotyping is predicted to be substantially more effective and potentially cost-saving compared with the current cytology-based screening programme undertaken every 2 years.

TL;DR: It is important to widely communicate that an initial increase in CIN2/3 and perhaps even invasive cervical cancer is expected after a national transition to primary HPV screening, that this phenomenon is due to increased prevalent disease detection, and that this effect represents a marker of screening success.

TL;DR: While numbers of women attending for screening and HPV tests are anticipated to initially fluctuate as a result of the transition to a longer recommended interval, there is expected to be less fluctuation in follow-up tests and procedures; however these will still have a significant impact on operational aspects of the screening program.

TL;DR: In primary HPV screening programs, partial genotyping for HPV16/18 or high-grade triage cytology in OHR HPV positive women can be used to refer the highest risk group to colposcopy, but 12-month follow-up for women with O HR HPV and low-grade cytology is associated with a low risk of developing cervical cancer.